Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE
Abstract Purpose Recent reports personalizing the administered activity (AA) of each cycle of peptide receptor radionuclide therapy based on the predicted absorbed dose (AD) to the kidneys (dose-limiting organ) have been promising. Assuming identical renal pharmacokinetics for each cycle is pragmati...
Main Authors: | Javian C. Malcolm, Nadia Falzone, Jennifer E. Gains, Matthew D. Aldridge, David Mirando, Boon Q. Lee, Mark N. Gaze, Katherine A. Vallis |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2022-03-01
|
Series: | EJNMMI Physics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40658-022-00436-4 |
Similar Items
-
p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids
by: Sara Lundsten, et al.
Published: (2021-11-01) -
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
by: Sarah Boughdad, et al.
Published: (2022-12-01) -
Research Progress of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety
by: MA Guangyu;BA Jiantao;PENG Cheng;CHEN Yingmao
Published: (2022-04-01) -
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
by: Hinke Siebinga, et al.
Published: (2023-08-01) -
Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough
by: Hinke Siebinga, et al.
Published: (2022-12-01)